Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1233-1243

  Dickinson, Laura ^a,b   Boffito, Marta ^c   Back, David ^b   Waters, Laura ^c   Else, Laura ^b   Davies, Geraint ^b   Khoo, Saye ^b   Pozniak, Anton ^c   Aarons, Leon ^d  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Chelsea and Westminster Foundation Trust   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Modelling; Pharmacokinetics; Simulation; Variability

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; ETHNICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POPULATION RESEARCH; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ADULT; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HUMAN EXPERIMENTATION; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; OLIGOPEPTIDES; PLASMA; PYRIDINES; RITONAVIR; YOUNG ADULT;

EID: 65749113553     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp102     Document Type: Article

References (26)

1. Bristol-Myers Squibb Pharmaceuticals Ltd. Reyataz® US Prescribing Information. http://packageinsertsbmscom/pi/pi_reyatazpdf (15 December 2008, date last accessed).
2. Bristol-Myers Squibb Pharmaceuticals Ltd. Reyataz® (atazanavir sulphate) 150, 200, 300 mg hard capsules Summary of Product Characteristics. http://emcmedicinesorguk/emc/assets/c/html/ DisplayDocasp?DocumentID=14145 (15 December 2008, date last accessed).
3. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63: 1679-93; discussion 94-5.
4. Perloff ES, Duan SX, Skolnik PR et al. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005; 33: 764-70.
5. Zhang D, Chando TJ, Everett DW et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729-39.
6. Kiser JJ, Lichtenstein KA, Anderson PL et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 2006; 26: 511-4.
7. Luber AD, Brower R, Kim D et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007; 8: 457-64.
8. Dailly E, Tribut O, Tattevin P et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 2006; 62: 523-6.
9. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6.
10. la Porte CJL, Back DJ, Blaschke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 4-14.
11. Colombo S, Buclin T, Cavassini M et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50: 3801-8.
12. Boffito M, Else L, Back D et al. Pharmacokinetics of atazanavir/ ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008; 13: 901-7.
13. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7.
14. Waters LJ, Moyle G, Bonora S et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12: 825-30.
15. Seminari E, Guffanti M, Villani P et al. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol 2005; 61: 545-9.
16. von Hentig N, Muller A, Rottmann C et al. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007; 51: 1431-9.
17. Dickinson L, Robinson L, Tjia J et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 82-90.
18. Kruse G, Staszewski S, Kurowski M. Drug monitoring of atazanavir in HIV-infected patients. In: 9th European AIDS Conference (EACS), Warsaw, Poland, 2003. Abstract LB4.2/13. http://www.eacs.eu/ conference/index.htm (15 December 2008, date last accessed).
19. Beal S, Sheiner LB. NONMEM® Users Guide. Ellicott City, Maryland, USA: ICON Development Solutions, 1989-1998.
20. Boffito M, Maitland D, Dickinson L et al. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 2006; 22: 749-56.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
22. Solas C, Gagnieu MC, Ravaux I et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit 2008; 30: 670-3.
23. Welage LS, Carver PL, Revankar S et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1431-8.
24. von Hentig N, Babacan E, Lennemann T et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62: 579-82.
25. von Hentig N, Dauer B, Haberl A et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63: 935-40.
26. Chetchotisakd P, Anunnatsiri S. Low-dose, once-daily atazanavir/ ritonavir (200/100): An effective treatment for HIV-infected patients in Thailand. J Acquir Immune Defic Syndr 2008; 49: 230-1.